

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/74, 31/785, 31/795</b>		<b>A1</b>	(11) International Publication Number: <b>WO 00/15239</b>
			(43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/AU99/00762 (22) International Filing Date: 13 September 1999 (13.09.99) (30) Priority Data: PP 5843                      14 September 1998 (14.09.98)    AU (71) Applicant (for all designated States except US): STARPHARMA LIMITED [AU/AU]; 343 Royal Pa- rade, Parkville, VIC 3052 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): <u>MATTHEWS</u> , Barry, Ross [AU/AU]; 9 Roy Road, Olinda, VIC 3788 (AU). <u>HOLAN</u> , George [AU/AU]; 86 Were Street, Brighton, VIC 3186 (AU). <u>MARDELL</u> , Karen, Wendy [AU/AU]; 59 Leila Road, Ormond, VIC 3204 (AU). (74) Agents: SLATTERY, John, M. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published With international search report.	

(54) Title: INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS

10e-4M BRI2923 Inhibition of 10e-5M Vpr P3  
Not Corrected



(57) Abstract

A method of prophylactic or therapeutic inhibition of a toxic material or substance in a human or non-human animal patient, comprises administration to the patient of an effective amount of a dendrimer having a plurality of terminal groups wherein at least one of the terminal groups has an anionic- or cationic-containing moiety bonded or linked thereto.